{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:05:05Z","timestamp":1758477905141,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Danish Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rheumatoid arthritis (RA) is a chronic inflammatory disease with fluctuating course of progression. Despite substantial improvement in treatments in recent years, treatment response is still not guaranteed. The aim of this study was to identify variation in Disease Activity Score 28 (DAS28) of RA patients in response to Tocilizumab, and to investigate both molecular and clinical factors influencing response. Clinical and biochemical data for 485 RA patients receiving Tocilizumab in combination with methotrexate were extracted from the LITHE phase III clinical study (NCT00106535), and post-hoc analysis conducted. Latent class mixed models were used to identify statistically distinct trajectories of DAS28 after the initiation of treatment. Biomarker measurements were then analysed cross-sectionally and temporally, to characterise patients by serological biomarkers and clinical factors. We identified three distinct trajectories of drug response: class 1 (n\u2009=\u200985, 17.5%), class 2 (n\u2009=\u2009338, 69.7%) and class 3 (n\u2009=\u200962, 12.8%). All groups started with high DAS28 on average (DAS28\u2009&gt;\u20095.1). Class 1 showed the least reduction in DAS28, with significantly more patients seeking escape therapy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Class 3 showed significantly higher rates of improvement in DAS28, with 58.1% achieving ACR response levels compared to 2.4% in class 1 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Biomarkers of inflammation, MMP-3, CRP, C1M, showed greater reduction in class 3 compared to the other classes. Identification of more homogenous patient sub-populations of drug response may allow for more targeted therapeutic treatment regimens and a better understanding of disease aetiology.<\/jats:p>","DOI":"10.1038\/s41598-020-70942-x","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T10:02:46Z","timestamp":1597744966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3248-7039","authenticated-orcid":false,"given":"J. P. M.","family":"Blair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-C.","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. H.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Brunak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"issue":"10055","key":"70942_CR1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388(10055), 2023\u20132038 (2016).","journal-title":"Lancet"},{"issue":"12","key":"70942_CR2","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/rheumatology\/keq169","volume":"49","author":"S Lloyd","year":"2010","unstructured":"Lloyd, S., Bujkiewicz, S., Wailoo, A. J., Sutton, A. J. & Scott, D. The effectiveness of anti-TNF- therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 49(12), 2313\u20132321. https:\/\/doi.org\/10.1093\/rheumatology\/keq169 (2010).","journal-title":"Rheumatology"},{"issue":"9","key":"70942_CR3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/acr.22289","volume":"66","author":"MA Karsdal","year":"2014","unstructured":"Karsdal, M. A. et al. Rheumatoid arthritis: a case for personalized health care?. Arthritis Care Res. 66(9), 1273\u20131280 (2014).","journal-title":"Arthritis Care Res."},{"issue":"2","key":"70942_CR4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrrheum.2017.220","volume":"14","author":"G Barturen","year":"2018","unstructured":"Barturen, G., Beretta, L., Cervera, R., Van Vollenhoven, R. & Alarc\u00f3n-Riquelme, M. E. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 14(2), 75\u201393 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"suppl 6","key":"70942_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/rheumatology\/kes279","volume":"51","author":"J Kay","year":"2012","unstructured":"Kay, J. & Upchurch, K. S. ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 51(suppl 6), 5\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kes279 (2012).","journal-title":"Rheumatology"},{"key":"70942_CR6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ebiom.2016.08.024","volume":"11","author":"DS Courvoisier","year":"2016","unstructured":"Courvoisier, D. S. et al. Rheumatoid arthritis patients after initiation of a new biologic agent: trajectories of disease activity in a large multinational cohort study. EBioMedicine 11, 302\u2013306 (2016).","journal-title":"EBioMedicine"},{"issue":"8","key":"70942_CR7","doi-asserted-by":"publisher","first-page":"e0135327","DOI":"10.1371\/journal.pone.0135327","volume":"10","author":"C Barnabe","year":"2015","unstructured":"Barnabe, C. et al. Heterogeneous disease trajectories explain variable radiographic, function and quality of life outcomes in the Canadian Early Arthritis Cohort (CATCH). PLoS ONE 10(8), e0135327. https:\/\/doi.org\/10.1371\/journal.pone.0135327 (2015).","journal-title":"PLoS ONE"},{"issue":"1\u20132","key":"70942_CR8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00831996","volume":"20","author":"CM Weyand","year":"1998","unstructured":"Weyand, C. M., Klimiuk, P. A. & Goronzy, J. J. Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes. Springer Semin. Immunopathol. 20(1\u20132), 5\u201322 (1998).","journal-title":"Springer Semin. Immunopathol."},{"issue":"2","key":"70942_CR9","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4555","volume":"16","author":"G Dennis","year":"2014","unstructured":"Dennis, G. et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res. Ther. 16(2), R90 (2014).","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"70942_CR10","doi-asserted-by":"publisher","first-page":"e0219980","DOI":"10.1371\/journal.pone.0219980","volume":"14","author":"JPM Blair","year":"2019","unstructured":"Blair, J. P. M., Bager, C., Platt, A., Karsdal, M. & Bay-Jensen, A.-C. Identification of pathological RA endotypes using blood-based biomarkers reflecting tissue metabolism: a retrospective and explorative analysis of two phase III RA studies. PLoS ONE 14(7), e0219980. https:\/\/doi.org\/10.1371\/journal.pone.0219980 (2019).","journal-title":"PLoS ONE"},{"issue":"5","key":"70942_CR11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.40428","volume":"70","author":"DE Orange","year":"2018","unstructured":"Orange, D. E. et al. Identification of three rheumatoid arthritis disease subtypes by machine learning integration of synovial histologic features and RNA sequencing data. Arthritis Rheumatol. (Hoboken, NJ) 70(5), 690\u2013701 (2018).","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"key":"70942_CR12","unstructured":"Wenzel, S. E. Phenotypes & endotypes emerging concepts on asthma heterogeneity. in Global Atlas of Asthma (EAACI) (2014)."},{"issue":"4","key":"70942_CR13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.semarthrit.2013.07.008","volume":"43","author":"AC Bay-Jensen","year":"2014","unstructured":"Bay-Jensen, A. C. et al. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin. Arthritis Rheum. 43(4), 470\u2013478 (2014).","journal-title":"Semin. Arthritis Rheum."},{"key":"70942_CR14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3899\/jrheum.120447","volume":"40","author":"RM Fleischmann","year":"2013","unstructured":"Fleischmann, R. M. et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J. Rheumatol. 40, 113\u2013126 (2013).","journal-title":"J. Rheumatol."},{"issue":"3","key":"70942_CR15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"JM Kremer","year":"2011","unstructured":"Kremer, J. M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 63(3), 609\u2013621 (2011).","journal-title":"Arthritis Rheum."},{"issue":"2","key":"70942_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v078.i02","volume":"78","author":"C Proust-Lima","year":"2017","unstructured":"Proust-Lima, C., Philipps, V. & Liquet, B. Estimation of extended mixed models using latent classes and latent processes: the R package lcmm. J. Stat. Softw. 78(2), 1\u201356 (2017).","journal-title":"J. Stat. Softw."},{"issue":"1","key":"70942_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates, D., M\u00e4chler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67(1), 1\u201348 (2015).","journal-title":"J. Stat. Softw."},{"key":"70942_CR18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ebiom.2016.08.024","volume":"11","author":"DS Courvoisier","year":"2016","unstructured":"Courvoisier, D. S. et al. Rheumatoid arthritis patients after initiation of a new biologic agent: trajectories of disease activity in a large multinational cohort study. EBioMedicine 11, 302\u2013306 (2016).","journal-title":"EBioMedicine"},{"issue":"2","key":"70942_CR19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.semarthrit.2012.01.004","volume":"42","author":"MA Karsdal","year":"2012","unstructured":"Karsdal, M. A. et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin. Arthritis Rheum. 42(2), 131\u2013139 (2012).","journal-title":"Semin. Arthritis Rheum."},{"issue":"5","key":"70942_CR20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/bmm.13.144","volume":"8","author":"AS Siebuhr","year":"2014","unstructured":"Siebuhr, A. S. et al. Biomarkers of cartilage and surrounding joint tissue. Biomark. Med. 8(5), 713\u2013731 (2014).","journal-title":"Biomark. Med."},{"issue":"4","key":"70942_CR21","doi-asserted-by":"crossref","first-page":"R86","DOI":"10.1186\/ar4266","volume":"15","author":"AS Siebuhr","year":"2013","unstructured":"Siebuhr, A. S. et al. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res. Ther. 15(4), R86 (2013).","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"70942_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0913-x","volume":"18","author":"AC Bay-Jensen","year":"2016","unstructured":"Bay-Jensen, A. C. et al. Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study. Arthritis Res. Ther. 18(1), 13 (2016).","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"70942_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41927-019-0052-0","volume":"3","author":"AC Bay-Jensen","year":"2019","unstructured":"Bay-Jensen, A. C. et al. Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. BMC Rheumatol. 3(1), 3. https:\/\/doi.org\/10.1186\/s41927-019-0052-0 (2019).","journal-title":"BMC Rheumatol."},{"issue":"10","key":"70942_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrg.2016.87","volume":"17","author":"JX Hu","year":"2016","unstructured":"Hu, J. X., Thomas, C. E. & Brunak, S. Network biology concepts in complex disease comorbidities. Nat. Rev. Genet. 17(10), 615\u2013629. https:\/\/doi.org\/10.1038\/nrg.2016.87 (2016).","journal-title":"Nat. Rev. Genet."},{"issue":"7","key":"70942_CR25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0895-4356(00)00363-2","volume":"54","author":"R Gijsen","year":"2001","unstructured":"Gijsen, R. et al. Causes and consequences of comorbidity: a review. J. Clin. Epidemiol. 54(7), 661\u2013674 (2001).","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"70942_CR26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5114\/ceji.2017.72807","volume":"42","author":"W Kurowska","year":"2017","unstructured":"Kurowska, W., Kuca-Warnawin, E. H., Radzikowska, A. & Ma\u015bli\u0144ski, W. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent. J. Immunol. 42(4), 390\u2013398 (2017).","journal-title":"Cent. J. Immunol."},{"issue":"10","key":"70942_CR27","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00296-015-3271-8","volume":"35","author":"W Katchamart","year":"2015","unstructured":"Katchamart, W., Koolvisoot, A., Aromdee, E., Chiowchanwesawakit, P. & Muengchan, C. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatol. Int. 35(10), 1693\u20131699. https:\/\/doi.org\/10.1007\/s00296-015-3271-8 (2015).","journal-title":"Rheumatol. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70942-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70942-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70942-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T18:18:21Z","timestamp":1670350701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70942-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70942"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70942-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2020,8,18]]},"assertion":[{"value":"5 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CLB, ACBJ, PF, MHT and MK are full-time employees at Nordic Bioscience, MK and ACBJ have stock in Nordic Bioscience. SB reports fees from Intomics. JPMB has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13975"}}